Fujian Wanchen Biotechnology Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Fujian Wanchen Biotechnology Group şu anda temettü ödemiyor.

Anahtar bilgiler

Temettü verimi

-2.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-2.5%
Gelecekteki Temettü Verimi	2.0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	CN¥0.220
Ödeme oranı	0%

Son temettü ve geri alım güncellemeleri

Recent updates

Fujian Wanchen Biotechnology Group's (SZSE:300972) Strong Earnings Are Of Good Quality

Nov 04

Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company

Oct 01

Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing

Sep 30

We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt

Aug 04

Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)

Jun 06

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 300972 şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 300972 şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Fujian Wanchen Biotechnology Group Piyasaya Karşı Temettü Getirisi

300972 temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (300972)	0%
Pazarın Alt %25'i (CN)	0.5%
Pazarın En İyi %25'i (CN)	2.1%
Sektör Ortalaması (Food)	2.2%
Analist tahmini (300972) (3 yıla kadar)	2.0%

Önemli Temettü: 300972 şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 300972 şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 300972 CN piyasası için dikkate değer bir temettü ödemiyor.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 300972 herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Fujian Wanchen Biotechnology Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Fujian Wanchen Biotechnology Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 06 June 2022

Fujian Wanchen Biotechnology Co., Ltd Announces Dividend for 2021

Fujian Wanchen Biotechnology Co., Ltd Proposes Final Cash Dividend for 2021

Recent updates

Consensus EPS estimates increase by 23%

Fujian Wanchen Biotechnology Group's (SZSE:300972) Strong Earnings Are Of Good Quality

Third quarter 2024 earnings released: EPS: CN¥0.47 (vs CN¥0.33 loss in 3Q 2023)

Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) Stock Rockets 28% But Many Are Still Ignoring The Company

Fujian Wanchen Biotechnology Group Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Return Trends At Fujian Wanchen Biotechnology Group (SZSE:300972) Aren't Appealing

New major risk - Share price stability

Price target increased by 11% to CN¥31.66

Second quarter 2024 earnings released: CN¥0.032 loss per share (vs CN¥0.38 loss in 2Q 2023)

New minor risk - Share price stability

Now 21% overvalued

We Think Fujian Wanchen Biotechnology Group (SZSE:300972) Is Taking Some Risk With Its Debt

Fujian Wanchen Biotechnology Group Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

Less than half of directors are independent

Sentiment Still Eluding Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972)

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Fujian Wanchen Biotechnology Group Co., Ltd., Annual General Meeting, May 13, 2024

Price target decreased by 27% to CN¥28.54

New minor risk - Shareholder dilution

Fujian Wanchen Biotechnology Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

New major risk - Share price stability

Third quarter 2023 earnings released: CN¥0.33 loss per share (vs CN¥0.23 profit in 3Q 2022)

Fujian Wanchen Biotechnology Co., Ltd Announces Management Appointments

New major risk - Earnings quality

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.38 loss per share (vs CN¥0.15 loss in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

Fujian Wanchen Biotechnology Co., Ltd to Report First Half, 2024 Results on Aug 19, 2023

First quarter 2023 earnings released: EPS: CN¥0.34 (vs CN¥0.16 in 1Q 2022)

Investor sentiment improves as stock rises 23%

Investor sentiment improves as stock rises 32%

Investor sentiment improves as stock rises 17%

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.063 loss in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.18 loss in 2Q 2021)

Fujian Wanchen Biotechnology Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date: 06 June 2022

Fujian Wanchen Biotechnology Co., Ltd Announces Dividend for 2021

Fujian Wanchen Biotechnology Co., Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.17 (vs CN¥0.84 in FY 2020)

Third quarter 2021 earnings released: CN¥0.063 loss per share (vs CN¥0.20 profit in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: CN¥0.18 loss per share (vs CN¥0.03 loss in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.22 in 1Q 2020)

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin